CliffBio
small molecule

PROLENSA

BROMFENAC SODIUM

Loss of exclusivityNovember 2033latest FDA-listed patent expiry
CompanyBAUSCH AND LOMB INC

Drug detail

Brand namePROLENSA
Active ingredientBROMFENAC SODIUM
StrengthEQ 0.07% ACID
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalApril 2013
Marketing statusRX

Listed patents

PatentExpiresType
9517220November 2033use U-1933
10085958November 2032product

More from BAUSCH AND LOMB INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PROLENSA patent cliff — loss of exclusivity November 2033 | CliffBio